BearingPoint Advises Wuhan On Billion-Dollar Biopharmaceutical Base
This article was originally published in PharmAsia News
Executive Summary
BearingPoint Management Consulting (Shanghai), subsidiary of BearingPoint, Inc., recently provided consulting services for Wuhan city on the establishment of its biopharmaceutical industrial base in the Donghu new technology development zone. This is a new milestone for BearingPoint as it represents the first customized biotechnology strategic planning project for China's leading high-tech zone. According to the ambitious plan, production value of the industry base is to reach RMB 14 billion, RMB 42 billion and RMB 130 billion by 2010, 2010-2015, and after 2020, respectively. Eventually, Donghu will make the biopharmaceutical industry its second production pillar worth hundreds of billion renminbi, after the electronics industry. (Click here for more - Chinese Language)